Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONTY $3.01 0.5000 +19.92%
CBMG $35.64 4.5100 +14.49%
BLRX $2.02 0.1700 +9.19%
XBIT $20.59 1.5400 +8.08%
INO $8.83 0.5700 +6.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CALA $11.00 -1.0200 -8.49%
TKAI $10.95 -0.9100 -7.67%
CLSN $2.63 -0.1701 -6.08%
CVM $0.75 -0.0400 -5.06%
BDSI $8.10 -0.3900 -4.59%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Lab-Made Skin Cells Will Aid Transplantation, Cancer, Drug Discovery Research, Say Penn Scientists

(Penn Medicine) Oct 26, 2011 - The pigmented cells called melanocytes aren't just for making freckles and tans. Melanocytes absorb ultraviolet light, protecting the skin from the harmful effects of the sun.
read press release 

Cancer Survivorship Research Must Look at Quality of Life

(Moffitt Cancer Center) Oct 28, 2011 - Assessing the quality of life experienced by cancer survivors is becoming increasingly important, say researchers at Moffitt Cancer Center in Tampa, Fla.
read press release 

Threshold Pharmaceuticals Reports Further Promising Data With TH-302 in Soft Tissue Sarcoma

(MarketWatch) Oct 28, 2011 - Threshold Pharmaceuticals, Inc. yesterday announced clinical trial results related to Threshold's Phase 3 clinical stage hypoxia-activated prodrug, TH-302.
read article 

Folate Receptors May Serve As a Front Door to Ovarian Cancer Treatment

(Georgia Health and Sciences University) Oct 28, 2011 - A new strategy that takes advantage of ovarian cancer’s reliance on folate appears to give relapse patients extra months of life with few side effects, researchers say.
read press release 

Herpes Virus Could Kill Aggressive Breast Cancer

(Fox News/MyHealthNewsDaily) Oct 26, 2011 - A genetically engineered version of the virus that causes herpes shows promise as a treatment for a particularly aggressive type of breast cancer, according to a new study in animals.
read article 

Postmastectomy Breast Reconstruction Grows in Use; However, Some Women Still May Not Have Equal Access to the Procedure

(American College of Surgeons) Oct 25, 2011 - Until now, studies looking at trends in cancer care have shown that immediate postmastectomy breast reconstruction has been underutilized.
read press release 

Surgeons Find Higher Than Expected Rate of Aggressive Rectal Cancer in Younger Adults

(American College of Surgeons) Oct 26, 2011 - University of Minnesota surgeons have confirmed a rising trend in rectal cancer in people age 40 and younger in recent years.
read press release 

Laparoscopic Surgeons Develop Fluorescent Light Technique to Improve Pancreatic Cancer Detection

(American College of Surgeons) Oct 24, 2011 - More than 80 percent of people with pancreatic cancer are diagnosed after the cancer has metastasized, and by then the prognosis for long-term survival is dismal. However, surgeons and scientists at the University of California-San Diego (UCSD) are developing a laparoscopic technique that uses fluorescent light to improve pancreatic cancer staging and treatment.
read press release 

Lilly Wins European Approval for New Use of Alimta

(Indianapolis Business Journal) Oct 28, 2011 - Indianapolis-based Eli Lilly and Co. said Friday that it has received European approval to use its lung cancer drug Alimta as a continuation maintenance therapy, potentially giving one of Lilly’s rising stars a new boost in sales.
read article 

New Study Examines Lower Costs to Medicare and Seniors For Cancer Care in the Physician Office Setting

(MarketWatch) Oct 27, 2011 - Leading cancer care advocates and providers gathered today to discuss the results of a new study that finds that per-patient-per-month (PPPM) chemotherapy service costs and patient copay amounts for Medicare beneficiaries are significantly lower in community-based care settings.
read article 

Research Makes It Possible to Predict How Cancers Will Respond to Chemo

(Dana-Farber Cancer Institute) Oct 27, 2011 - A discovery by scientists at Dana-Farber Cancer Institute suggests that it may be possible to predict which cancer patients are most likely to benefit from chemotherapy, as well as to make chemotherapy drugs more effective by pushing tumor cells closer to the point of suicide.
read press release 

Aspirin Slashes Hereditary Cancer Risk in UK Study

(Reuters) Oct 28, 2011 - Taking two aspirin a day for two years reduces the long-term risk of bowel cancer in people with a family history of the disease by around 60 percent, according to a British study published Friday.
read article 

F.T.C.: 28 ‘Pay-for-Delay’ Generic Drug Deals

(NYT/Prescriptions blog) Oct 25, 2011 - Drug companies negotiated 28 potential “pay-for-delay” deals that slowed the marketing of cheaper generic drugs in the fiscal year ending Sept. 30, the Federal Trade Commission said Tuesday in a staff report.
read article 

FDA Invests $2 Million in Partnerships Through Centers of Excellence in Regulatory Science and Innovation

(FDA) Oct 26, 2011 - The U.S. Food and Drug Administration today announced the award of $2 million to support two regional Centers of Excellence in Regulatory Science and Innovation (CERSI).
read press release 

Pfizer in Research Collaboration With Medco

(Reuters) Oct 26, 2011 - Pfizer Inc, the world's largest drugmaker, and pharmacy benefit manager Medco Health Solutions Inc said on Wednesday they had set up a research collaboration aimed at better identifying the patients most likely to be helped by a new medicine.
read article 

Gilead, Bristol-Myers Squibb Ink Deal For HIV-Fighting Booster

(San Francisco Business Times blog) Oct 26, 2011 - Bristol-Myers Squibb Co. will develop a new HIV treatment combining its protease inhibitor Reyataz and Gilead Sciences Inc.’s new boosting agent cobicistat, according to a deal announced Wednesday.
read article 

FDA Delays Verdict on Astra/Bristol Diabetes Pill

(Reuters) Oct 26, 2011 - U.S. drug regulators said they need three more months to decide whether to approve a new type of diabetes pill from AstraZeneca and Bristol-Myers Squibb.
read article 

PathForward Oncology, LLC, Names Brian J. Litten Chief Executive Officer

(Market Watch) Oct 26, 2011 - The management committee of PathForward Oncology, LLC, a joint venture between CareCore National and D3 Oncology Solutions, an affiliate of UPMC Cancer Centers, announced today the appointment of Brian J. Litten as its first chief executive officer.
read article 

Seattle Genetics Appoints Vice President, Medical Affairs and Announces Vice President, Quality Management Promotion

(Seattle Genetics) Oct 26, 2011 - Seattle Genetics, Inc. today announced the appointment of James Kyle Bryan, M.D., as Vice President, Medical Affairs. Dr. Bryan is a hematologist and medical oncologist, and brings more than 18 years of experience in oncology drug development.
read corporate press release 

Dee Dee Ricks Changes the Course of Her Life After Discovering She Had Breast Cancer

(NY Daily News) Oct 26, 2011 - Dee Dee Ricks doesn't like to look at what she was in 2007, when she was a high-flying hedge fund consultant focused more on money than life.
read article 

Moffitt, US Oncology Network Join Forces

(Tampa Bay Business Journal) Oct 27, 2011 - Moffitt Cancer Center and The US Oncology Network will collaborate to develop and operate community-based cancer centers throughout Florida.
read article 

UCSF-Pfizer Partnership Yields Projects Aimed at Clinical Trials

(UCSF) Oct 26, 2011 - An 11-month-old partnership between UCSF and Pfizer, Inc., aimed at rapidly moving new therapies into human clinical trials, has selected its first projects for funding and joint development.
read press release 

Biovest Announces That FDA Grants Orphan Drug Status For Personalized Cancer Vaccine For The Treatment of Waldenstrom’s Macroglobulinemia, a Rare Subtype of Non-Hodgkin’s Lymphoma

(TheStreet) Oct 27, 2011 - Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID® for the treatment of Waldenstrom’s macroglobulinemia, a rare subtype of B-cell non-Hodgkin’s lymphoma.
read article 

FDA Schedules Delcath Pre-New Drug Application Meeting Date

(Yahoo! Finance) Oct 26, 2011 - Delcath Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has responded to the Company's request made in September for a pre-New Drug Application (NDA) meeting and has scheduled a date in mid-January 2012.
read article 

Obstacles With Oncology For Newly Diagnosed Patients

(The Oregonian) Oct 27, 2011 - New research shows that recently diagnosed patients frequently face challenges getting an appointment with an oncologist, regardless of their health insurance status.
read article